MedTrace Logo

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

NCT05377242 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2025-11-26

No results posted yet for this study

Summary

This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a decentralized clinical trial (DCT) design in which individuals can participate from anywhere in the United States. Recruitment efforts will be designed to obtain a geographically and demographically diverse study sample.

Conditions

  • Gulf War Illness

Interventions

DIETARY_SUPPLEMENT

Curcumin

Curcumin (chemical C21H20O6) is derived from turmeric (Curcuma longa) root extract, standardized to contain 95% curcuminoids. The greatest obstacle with curcumin is its poor natural bioavailability. To help circumvent that issue, a piperazine is included as black pepper 5.3mg (Piper nigrum) fruit extract standardized to 95% piperine. The botanical we are using is provided by Pure Encapsulations. Curcumin being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug. 100 participants will be randomized to receive curcumin. Participants will receive placebo, low-dose (500 mg/day), medium-dose (1000 mg/day), and/or high dose (2000 mg/day) curcumin in a randomized order.

DIETARY_SUPPLEMENT

Resveratrol

Resveratrol (chemical C14H12O3) is provided as 99% Pure Trans-Resveratrol (MegaResveratrol) from polygonum cuspidatum root). Resveratrol being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug. 100 participants will be randomized to receive resveratrol. Participants will receive placebo, low-dose (250 mg/day), medium-dose (500mg/day), and/or high dose (1000mg/day) resveratrol in a randomized order.

DIETARY_SUPPLEMENT

Stinging Nettle

Stinging nettle is derived from nettle (Urtica spp) leaf. The botanical we are using is provided by Pure Encapsulations. Stinging Nettle being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug. 100 participants will be randomized to receive stinging nettle. Participants will receive placebo, low-dose (435mg/day), medium-dose (870mg/day), and/or high dose (2610mg/day) stinging nettle in a randomized order.

Sponsors & Collaborators

  • Congressionally Directed Medical Research Programs

    collaborator FED

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Jarred Younger, PhD · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05377242 on ClinicalTrials.gov